GLP1R and Insulin resistance: Finally, to strengthen the GLP1-RAs potential benefit effect on HPG axis, in studies conducted in obese PCOS women treated with GLP1-RAs (liraglutide and exenatide), amelioration of insulin resistance, reduction of hyperandrogenemia, improvement of ovulation rates, and restored menstrual cyclicity were observed (40–42).